SC
AUPH icon

Sculptor Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Sculptor Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-185,100
Closed -$1.16M – 18
2017
Q3 		$1.16M Sell
185,100
-4,800
-3% -$30.3K 0.01% 246
2017
Q2 		$1.16M Buy
+189,900
New +$1.28M 0.01% 245

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sculptor Capital's AUPH Position: Q4 2017 in Review

Sculptor Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2017, closing a stake of 185,100 shares — an estimated $1.16M sold.

Sculptor Capital first reported a position in AUPH in Q2 2017 and held it in 2 quarters. The position peaked at $1.16M in Q2 2017. 68 funds tracked by Wall St. Rank hold AUPH as of Q4 2017.

  • Sculptor Capital reported no remaining Aurinia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Sculptor Capital sold 185,100 Aurinia Pharmaceuticals shares in Q4 2017, an estimated $1.16M.
  • Sculptor Capital first reported a position in Aurinia Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Sculptor Capital's Aurinia Pharmaceuticals position peaked at $1.16M in Q2 2017.
  • 68 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2017.

Based on Sculptor Capital's 13F filing for Q4 2017, filed 13 Feb 2018.